



Harnessing the power of T cell measurement

Press Release

At Oxford Immunotec: Dr Peter Wrighton-Smith, CEO Tel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email: info@oxfordimmunotec.com	Oxford Immunotec 94C Milton Park Abingdon Oxfordshire OX14 4RY, UK
--	---

Study results suggest the utility of T-SPOT[®].TB in monitoring treatment for latent TB infection (LTBI)

Oxford, UK; 10th September 2007 – Oxford Immunotec Ltd, the T cell measurement company, today announced the publication of a recent study demonstrating the potential use of T-SPOT.TB in monitoring anti-LTBI treatment.

In this study reported in the American Journal of Respiratory and Critical Care Medicine Chee *et al* investigated the close contacts of smear or culture positive subjects who were treated with standard chemoprophylaxis therapy and were then followed up with a T-SPOT.TB test following completion of this therapy.

This study showed that at the completion of LTBI therapy 38% of the subjects reverted to a negative T-SPOT.TB result. Moreover, in subjects who were only positive to CFP 10, one of the two antigens in the T-SPOT.TB assay, 65% reverted to a negative T-SPOT.TB result.

These findings suggest that the quantitative response to CFP 10 may be a potentially useful treatment monitoring tool.

Commenting on the results, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said "this study provides additional evidence that the T-SPOT.TB test may have a role to play as an additional tool in the monitoring of anti-TB treatments. Treatment monitoring in TB infection is particularly important since the treatment period is typically six months or longer. Additionally, the test may become one of the few tools available to clinicians to monitor the effectiveness of treatment in MDR-TB and XDR-TB, which are becoming more prevalent".

- ENDS -

Notes to editors:

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT[®] technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person's cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT[®].TB

T-SPOT.TB is an *in vitro* T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding \$1bn.

Unlike the traditional Tuberculin Skin Test, the T-SPOT.TB test incorporates a positive control, allowing the user to distinguish between a genuine negative result and one which is indeterminate (i.e. an inconclusive result) as a result of a technical failure.

T-SPOT is a trademark of Oxford Immunotec.

Journal Reference

Chee C, KhinMar KW, Gan SH, Barkham TMS, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-Cell responses to *M. tuberculosis*-specific antigens.

AM J Respir Crit Care Med. Vol 175. pp 282-287, 2007.